Generic Drugs Settlement
Generic Drug Price-Fixing Settlements · In re Generic Pharmaceuticals Pricing Antitrust Litigation
Health plans, pharmacies, hospitals, and direct purchasers that bought or reimbursed generic drugs between 2009 and 2024 may be eligible for compensation. A $275 million settlement with Sandoz and Fougera has been reached, and additional settlements with other manufacturers are expected.
| Settlement fund | $275M+ — Initial settlements — more expected |
|---|---|
| Class period | 2009 – 2024 (varies by purchaser class) |
| Defendants | Sandoz, Fougera Pharmaceuticals, and other generic manufacturers (litigation ongoing) |
| Filing status | Deadlines vary by class — contact us to confirm yours |
| Cost to file with VMC | $0 upfront — contingency only, paid from recovered funds |
The case
Multiple lawsuits allege that the largest generic drug manufacturers conspired to fix prices and allocate markets in violation of federal antitrust law — inflating the cost of hundreds of common medications for more than a decade.
A $275 million agreement with Sandoz and Fougera Pharmaceuticals is the first major recovery, and litigation against additional manufacturers continues. Filing now positions your organization for current and future distributions.
Who qualifies
- Direct purchasers: bought eligible generic drugs directly from defendant manufacturers between May 1, 2009 and December 31, 2019
- Indirect purchasers: self-funded health plans, unions, municipalities, and similar entities that paid for or reimbursed generic drugs (not for resale) between January 1, 2010 and March 5, 2024, in any U.S. state except Indiana and Ohio
- Pharmacies, hospitals, and clinics that dispensed the drugs at issue between January 1, 2010 and March 4, 2024 and purchased from specified wholesalers
Eligibility rules are set by the court and the claims administrator. The fastest way to know for sure is a free eligibility review — we'll tell you plainly whether you have a claim worth filing.
What you'll need
- Tax ID (TIN/EIN) and entity contact information
- Pharmacy license number and issue date, if filing as a pharmacy
- Purchase or reimbursement data for the relevant period — our team provides a claims worksheet and helps assemble it
How filing works
- Free eligibility review. We confirm your business fits the class definition — no cost, no commitment.
- Sign the service agreement. One signature. Our fee is a percentage of recovery, paid only if you're paid.
- We assemble the claim. You receive a short claims worksheet; our analysts compile and verify the supporting data.
- We file and defend it. We submit before the deadline and respond to any administrator deficiency notices.
- You get paid. Funds are distributed by the administrator; we track your claim through to payment.
Official case information is available from the court-approved settlement website and the claims administrator. VMC Group is not the claims administrator and is not affiliated with the court; class members may always file directly at no cost.
Generic Drugs Settlement FAQs
My organization is a self-funded health plan. Do we qualify?
Very likely yes, if you paid for or reimbursed generic drugs between January 1, 2010 and March 5, 2024 and operate outside Indiana and Ohio. Self-funded plans, unions, and municipalities are exactly the entities the indirect purchaser class covers.
Which drugs are covered by the generic drug settlement?
The cases cover hundreds of widely dispensed generic medications. We review your dispensing or reimbursement data against the eligible drug list as part of our free eligibility review.
Will there be more generic drug settlements?
Litigation against other manufacturers is ongoing, and additional settlements are expected. Clients who file now are positioned for both current and future distributions.
Find out what your business is owed — in one call.
No upfront cost. No obligation. If you don't recover, you don't pay.